MK 8291
Latest Information Update: 25 Jul 2023
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postherpetic neuralgia
Most Recent Events
- 25 Jul 2023 Discontinued - Preclinical for Postherpetic neuralgia in United Kingdom (PO)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Postherpetic-neuralgia in United Kingdom (PO, Tablet)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Postherpetic-neuralgia in Bulgaria (PO, Tablet)